[Guest1]

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma

by Guest1 on Sat Jun 02, 2012 1:17 pm

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells: http://www.news-medical.net/news/20120602/Inhibiting-IRE1ceb1-XBP1-pathway-impacts-survival-of-myeloma-cells.aspx

This study suggests a promising therapeutic option in multiple myeloma. What do you think?

[terryl1]

Re: Inhibiting IRE1α-XBP1 pathway impacts survival of myelom

by terryl1 on Sat Jun 02, 2012 1:39 pm

Thanks for the link. It does sound promising. Dana Farber really seems like it is on the cutting edge of novel myeloma therapies---in addition to this, JQ1 emanates from the lab of Dana Farber doctor Bradner and other Dana Farber doctors have developed a cocktail of peptides approach which will soon be used in smoldering multiple myeloma cases to see if it can halt progression to active myeloma. That trial is set to start this year at Mass General in Boston and other locations. The company is Oncopep and several Dana Farber doctors are involved with it vis-a-vis the peptides trial. Terry

[Dan D]

Re: Inhibiting IRE1α-XBP1 pathway impacts survival of myelom

by Dan D on Sat Jun 02, 2012 2:17 pm

Dana Farber is also the home of Kenneth Anderson, a leading myeloma physician, researcher, and "thought leader" who is involved in many of these studies, and who, perhaps more pertinently, is not a big fan of transplants -- hence his quest for novel treatments based on cutting edge science that offer long-lasting control and ultimately a cure.